How Ketamine Affects the Brain: What Mood Research Shows
An introduction to glutamate, NMDA receptors, and neuroplasticity that explains the limits of laboratory research and why it does not prove benefits from compounded ketamine.
Share
Ketamine research has drawn attention to glutamate, a chemical messenger involved in communication between brain cells. Understanding that research can be useful, provided a proposed biological mechanism is kept separate from proof that a particular treatment works.
Important: Compounded ketamine is not FDA-approved. FDA has not reviewed these products for safety, effectiveness, or quality before marketing. Ketamine is not FDA-approved for psychiatric conditions. Compounded nasal spray is different from FDA-approved esketamine (Spravato), which is administered in certified healthcare settings. Read FDA's explanation of compounded drugs.
What is the glutamate connection?
Ketamine affects NMDA receptors, which are part of the glutamate signaling system. Researchers study how those effects influence other signaling pathways and communication within brain networks. The full explanation for antidepressant effects is still being investigated.
What does neuroplasticity mean?
Neuroplasticity describes the nervous system's capacity to change its connections and activity. It does not mean that a drug has been shown to “reset” a person's brain or erase an illness.
A 2019 NIH-supported study in mice examined connections on nerve cells after stress and ketamine treatment. The findings helped researchers investigate mechanisms related to sustained behavioral changes. A mouse study does not demonstrate repair of a patient's brain or prove benefits from compounded nasal spray.
Does a mechanism establish an outcome?
No. Changes in a receptor, protein, or brain image are different from a demonstrated improvement in daily life. Human treatment studies must examine symptoms, adverse effects, follow-up, and the specific medication used. A mechanism proposed for depression also does not establish effectiveness for anxiety, PTSD, or every other condition.
What can patients take from the science?
Ask your clinician which clinical evidence applies to your diagnosis and the formulation being considered. Findings from intravenous ketamine or FDA-approved esketamine should not be presented as proof of safety or effectiveness for a compounded at-home spray.
If treatment is considered, establish goals that can be reviewed over time. Mood ratings, sleep, participation in daily activities, and adverse effects are more useful topics for follow-up than whether you experienced a “brain reset.” Do not change your dose to try to produce a particular mental state.
Risks and the treatment setting
Ketamine can cause sedation, dissociation, impaired thinking or coordination, increased blood pressure, and slowed breathing. Abuse, misuse, dependence, worsening psychiatric symptoms, and urinary or bladder problems are additional concerns. A prescription or lower dose does not eliminate these risks.
At home, a healthcare professional is not onsite to monitor you or respond immediately to a serious reaction. Virtual visits and follow-up support do not provide the same monitoring as an onsite healthcare team. Discuss your medications, health history, monitoring needs, and emergency plan with your clinician.
Discuss your options
Bliss Mist Rx LLC provides telehealth services and does not compound or manufacture medications. A licensed clinician determines whether treatment is appropriate. A consultation does not guarantee a prescription. If prescribed, medication is dispensed by an independent, appropriately licensed compounding pharmacy.
Book a Free Virtual Appointment or Follow-Up.
This article is general education and does not replace individualized medical advice.
